TP53 and acute myeloid leukemia: In a recent multi-center report of 291 patients with TP53 mutated AML, treated with various induction regimens, complete remission with or without count recovery (CR/CRi), was achieved in only 29%, and 46 patients were bridged to ASCT [17]; in the particular study, HMA + venetoclax combination therapy was the most successful in inducing CR/CRi and outcome was favorably influenced by ASCT and not TP53 variant allele frequency.